MANATEE-T1D: Metformin ANd AutomaTEd insulin delivery system Effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with Type 1 Diabetes

MANATEE-T1D：二甲双胍和自动胰岛素输送系统对 1 型糖尿病青年肾血管阻力、胰岛素敏感性和心脏代谢功能的影响

• 批准号: 10674617
• 负责人: Kalie L Tommerdahl
• 金额: $ 18.88万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674617
• 关键词: Acceleration; Address; Adipose tissue; Adopted; Affect; Algorithms; American; Aorta; Artificial Pancreas; Attenuated; Biometry; Biopsy; Blood Vessels; Body Composition; Body fat; Cardiovascular Diseases; Cardiovascular Physiology; Cardiovascular system; Caring; Cessation of life; Childhood; Clinical Trials; Complex; Continuous Glucose Monitor; Data Analyses; Data Collection; Dedications; Development Plans; Diabetes Mellitus; Diabetic Nephropathy; Disease; Dose; Endocrinology; Endothelial Cells; Endothelium; Environment; Exposure to; Fatty acid glycerol esters; Foundations; Functional disorder; Funding; Future; Glomerular Filtration Rate; Glucose; Glucose Clamp; Goals; Grant; Hematocrit procedure; Hepatic; Hybrids; Hyperglycemia; Hyperinsulinism; Hypoglycemia; Immunofluorescence Immunologic; Incidence; Individual; Infusion procedures; Injections; Insulin; Insulin Infusion Systems; Insulin Resistance; Insulin deficiency; Insulin-Dependent Diabetes Mellitus; Intervention; Iohexol; Kidney; Longevity; Measures; Mentorship; Metabolic; Metabolic dysfunction; Metformin; Methods; Morbidity - disease rate; Nephrology; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Outcome; Performance; Peripheral; Personnel Management; Persons; Publications; Randomized; Regimen; Renal Plasma Flow; Research; Research Design; Research Methodology; Risk; Sampling; System; Technology; Testing; Time; Training; Translational Research; Vascular Diseases; Vascular Endothelial Cell; Vascular Endothelium; Vascular resistance; Weight Gain; Work; Youth; aged; arterial stiffness; attenuation; cardiometabolism; cardiovascular disorder risk; career; career development; cell injury; double-blind placebo controlled trial; endothelial dysfunction; euglycemia; experience; fasting glucose; glycemic control; high risk; improved; in vivo; innovation; instructor; insulin sensitivity; insulin sensitivity/resistance; kidney dysfunction; kidney vascular structure; mortality; multidisciplinary; new technology; patient oriented research; peer; pharmacologic; pressure; professor; protein expression; randomized placebo controlled trial; research study; risk mitigation; standard measure; therapeutic development

PROJECT SUMMARY/ABSTRACT: Diabetic kidney disease (DKD) and cardiovascular disease (CVD) remain the leading causes of morbidity and mortality in people with type 1 diabetes (T1D) and are exacerbated with longer duration of diabetes and time outside goal glycemic range. Yet, T1D is a complex disease with pathophysiology that extends beyond -cell injury and insulin deficiency to include insulin resistance (IR) and renal vascular resistance (RVR), factors that accelerate CVD risk. We have shown that metformin improved peripheral insulin sensitivity (IS) and vascular stiffness in youth with T1D on multiple daily insulin injections (MDI) or standard insulin pumps. However, metformin’s effect on kidney and endothelial outcomes, and the effects of T1D technologies, with or without metformin, on any CV or kidney outcome, remains unknown. Automated insulin delivery (AID) systems combine an insulin pump, continuous glucose monitor (CGM), and control algorithm to modulate background insulin delivery and decrease peripheral insulin exposure while improving time in target range and reducing hypoglycemia. We hypothesize that AID systems, particularly when combined with metformin, may modulate RVR and IS, thereby impacting cardiometabolic function. MANATEE-T1D is a randomized, double-blind, placebo-controlled trial of 4 months of metformin 2,000 mg daily in 30 youth aged 12-21 years with T1D on AID systems vs. 15 control youth with T1D on MDI/CGM which will assess for changes in calculated RVR and gold standard measures of whole-body and adipose IS, arterial stiffness, and endothelial function. As an Instructor/Fellow in Pediatric Endocrinology with a strong publication and grant funding record, I am establishing myself in the burgeoning field of T1D technologies by developing a unique niche studying the effects of diabetes technologies, with or without combination pharmacological therapies, on IS and kidney and cardiovascular complications in youth with T1D. A K23 would support the following research goals: 1) define longitudinal differences in RVR by p-aminohippurate clearance and IS by hyperinsulinemic-euglycemic clamp in youth with T1D on metformin and AID systems, 2) test for associations between RVR and IS, 3) evaluate for in vivo and ex vivo endothelial function changes with metformin and AID systems. My career development plan includes dedicated time to 1) train in the performance and analysis of gold standard translational research methods for RVR, IS, arterial stiffness, and endothelial function, 2) gain experience conducting patient-oriented research studies including study design and execution, data collection and analysis, and personnel management, 3) work with a multidisciplinary team of experts in Endocrinology, Nephrology, and Biostatistics, and 4) establish the foundation for an independent research career aimed at developing novel technologies while leveraging existing therapies to mitigate the risk for DKD and CVD across the lifespan. My training environment will be outstanding with mentorship from Drs. Kristen Nadeau (Professor, Ped. Endocrinology) and Jessica Kendrick (Professor, Nephrology), experts in clinical trials, diabetes, IS, DKD, and CVD.

项目总结/文摘:

项目成果

Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.

• DOI: 10.1080/14656566.2023.2203319
• 发表时间: 2023-06
• 期刊: EXPERT OPINION ON PHARMACOTHERAPY
• 影响因子: 3.2
• 作者: Tommerdahl, Kalie L.;Kula, Alexander J.;Bjornstad, Petter
• 通讯作者: Bjornstad, Petter

Response to Letter to the Editor Entitled "The Missing Link Between Coffee Consumption and AKI - Water".

• DOI: 10.1016/j.ekir.2022.09.015
• 发表时间: 2022-11
• 期刊: KIDNEY INTERNATIONAL REPORTS
• 影响因子: 6
• 作者: Tommerdahl, Kalie L.;Bjornstad, Petter;Rebholz, Casey M.;Parikh, Chirag R.
• 通讯作者: Parikh, Chirag R.

Coffee Consumption May Mitigate the Risk for Acute Kidney Injury: Results From the Atherosclerosis Risk in Communities Study.

• DOI: 10.1016/j.ekir.2022.04.091
• 发表时间: 2022-07
• 期刊: KIDNEY INTERNATIONAL REPORTS
• 影响因子: 6
• 作者: Tommerdahl, Kalie L.;Hu, Emily A.;Selvin, Elizabeth;Steffen, Lyn M.;Coresh, Josef;Grams, Morgan E.;Bjornstad, Petter;Rebholz, Casey M.;Parikh, Chirag R.
• 通讯作者: Parikh, Chirag R.

A Pilot Study of the Safety and Efficacy of Alkali Therapy on Vascular Function in Kidney Transplant Recipients.

• DOI: 10.1016/j.ekir.2021.06.006
• 发表时间: 2021-09
• 期刊: Kidney international reports
• 影响因子: 6
• 作者: Bohling R;Grafals M;Moreau K;You Z;Tommerdahl KL;Bjornstad P;Stenson EK;Andrews E;Ramirez-Renteria L;Kendrick J
• 通讯作者: Kendrick J

The Evaluation of Coffee Therapy for Improvement of Renal Oxygenation (COFFEE) Study: A Mechanistic Pilot and Feasibility Study Evaluating Coffee's Effects on Intrarenal Hemodynamic Function and Renal Energetics.

• DOI: 10.1016/j.ekir.2022.04.096
• 发表时间: 2022-07
• 期刊: KIDNEY INTERNATIONAL REPORTS
• 影响因子: 6
• 作者: Tommerdahl, Kalie L.;Vinovskis, Carissa;Li, Lu-Ping;Rebholz, Casey M.;Severn, Cameron;Hu, Emily A.;Selvin, Elizabeth;Coresh, Josef;Grams, Morgan E.;Prasad, Pottumarthi;Parikh, Chirag R.;Bjornstad, Petter
• 通讯作者: Bjornstad, Petter